Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Lifevantage Corporation stock logo
LFVN
Lifevantage
$12.53
-0.8%
$12.66
$5.22
$27.38
$157.73M0.43146,626 shs93,634 shs
MediWound Ltd. stock logo
MDWD
MediWound
$19.09
-1.7%
$19.36
$13.49
$24.00
$206.32M0.3891,057 shs55,739 shs
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
$0.00
$1.22
$8.45
$45.46M1.5329,344 shs348 shs
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
$2.97
-2.3%
$3.26
$2.65
$9.55
$164.35M0.82479,783 shs666,758 shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Lifevantage Corporation stock logo
LFVN
Lifevantage
0.00%+0.80%-5.08%-18.95%+87.29%
MediWound Ltd. stock logo
MDWD
MediWound
0.00%-6.51%-6.15%+17.33%+30.84%
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
0.00%0.00%0.00%0.00%+4,900.00%
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
0.00%-10.00%-0.67%-23.45%-63.60%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Lifevantage Corporation stock logo
LFVN
Lifevantage
3.9518 of 5 stars
3.50.01.72.72.61.71.3
MediWound Ltd. stock logo
MDWD
MediWound
1.575 of 5 stars
3.51.00.00.00.00.80.6
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
3.9049 of 5 stars
3.61.00.04.62.31.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Lifevantage Corporation stock logo
LFVN
Lifevantage
3.00
Buy$30.50143.42% Upside
MediWound Ltd. stock logo
MDWD
MediWound
3.00
Buy$31.8066.58% Upside
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
0.00
N/AN/AN/A
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
3.13
Buy$13.39350.84% Upside

Current Analyst Ratings Breakdown

Latest NBRV, MDWD, LFVN, and VYGR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/2/2025
MediWound Ltd. stock logo
MDWD
MediWound
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$34.00
5/22/2025
MediWound Ltd. stock logo
MDWD
MediWound
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$25.00 ➝ $31.00
5/2/2025
MediWound Ltd. stock logo
MDWD
MediWound
Alliance Global Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$25.00
4/8/2025
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Lifevantage Corporation stock logo
LFVN
Lifevantage
$200.16M0.79$0.88 per share14.21$2.05 per share6.11
MediWound Ltd. stock logo
MDWD
MediWound
$20.22M10.21N/AN/A$2.89 per share6.61
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
$35.59M0.00N/AN/A$0.10 per share0.00
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
$80M2.05N/AN/A$5.49 per share0.54
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Lifevantage Corporation stock logo
LFVN
Lifevantage
$2.94M$0.6918.16N/A4.12%34.67%15.24%8/27/2025 (Estimated)
MediWound Ltd. stock logo
MDWD
MediWound
-$30.22M-$2.09N/AN/AN/A-110.45%-74.12%-30.92%8/13/2025 (Estimated)
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
-$57.19M-$19.20N/AN/AN/A-148.11%-365.53%-135.81%N/A
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
-$65M-$1.46N/AN/AN/A-126.49%-27.36%-21.06%8/5/2025 (Estimated)

Latest NBRV, MDWD, LFVN, and VYGR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/21/2025Q1 2025
MediWound Ltd. stock logo
MDWD
MediWound
-$0.65-$0.07+$0.58-$0.07$5.20 million$3.96 million
5/6/2025Q3 2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.16$0.26+$0.10$0.26$60.99 million$58.44 million
5/6/2025Q1 2025
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
-$0.35-$0.53-$0.18-$0.53$13.55 million$6.47 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.181.44%N/A26.09%3 Years
MediWound Ltd. stock logo
MDWD
MediWound
N/AN/AN/AN/AN/A
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
N/AN/AN/AN/AN/A
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
N/AN/AN/AN/AN/A

Latest NBRV, MDWD, LFVN, and VYGR Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/29/2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
quarterly$0.04501.5%5/30/20255/30/20256/13/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Lifevantage Corporation stock logo
LFVN
Lifevantage
N/A
1.66
0.98
MediWound Ltd. stock logo
MDWD
MediWound
N/A
2.15
1.99
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
0.12
0.85
0.52
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
N/A
6.10
6.10

Institutional Ownership

CompanyInstitutional Ownership
Lifevantage Corporation stock logo
LFVN
Lifevantage
35.32%
MediWound Ltd. stock logo
MDWD
MediWound
46.83%
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
0.27%
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
48.03%

Insider Ownership

CompanyInsider Ownership
Lifevantage Corporation stock logo
LFVN
Lifevantage
20.65%
MediWound Ltd. stock logo
MDWD
MediWound
9.20%
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
1.63%
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
6.39%
CompanyEmployeesShares OutstandingFree FloatOptionable
Lifevantage Corporation stock logo
LFVN
Lifevantage
26012.59 million9.99 millionOptionable
MediWound Ltd. stock logo
MDWD
MediWound
8010.81 million9.81 millionOptionable
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
7032.02 million31.49 millionNot Optionable
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
10055.34 million51.80 millionOptionable

Recent News About These Companies

Voyager Technologies Soars with IPO Success
Cantor Fitzgerald Estimates VYGR FY2026 Earnings
Voyager Technologies Shares Soar In Market Debut
Voyager raises $383 million from upsized IPO
Voyager Therapeutics, Inc. stock logo
Brokers Issue Forecasts for VYGR FY2026 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Lifevantage stock logo

Lifevantage NASDAQ:LFVN

$12.53 -0.10 (-0.79%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$12.52 0.00 (-0.04%)
As of 06/20/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.

MediWound stock logo

MediWound NASDAQ:MDWD

$19.09 -0.34 (-1.75%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$19.14 +0.05 (+0.24%)
As of 06/20/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

Nabriva Therapeutics stock logo

Nabriva Therapeutics NASDAQ:NBRV

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.

Voyager Therapeutics stock logo

Voyager Therapeutics NASDAQ:VYGR

$2.97 -0.07 (-2.30%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$3.05 +0.08 (+2.83%)
As of 06/20/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.